GMAB News and Press, Genmab A/S From 09/25/23

Company Announcement TEPKINLY ® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy Conditio...

Subcutaneous EPKINLY ™ (epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy Approval based on results of...

2023-09-12 03:25:00 ET Summary Equity investors must gain a greater understanding of how companies are impacted by and addressing deforestation—and how different approaches might affect long-term return potential. Beyond its ties to climate and biodiversity, deforestation i...

2023-09-05 11:16:44 ET Shares of Zai Lab (NASDAQ: ZLAB) were up more than 10% as of 11 a.m. on Tuesday. The Chinese biotech stock rose after the company announced positive phase 3 trial data regarding Tivdak as a front-line therapy to treat metastatic cervical cancer in patients...

2023-09-05 07:10:57 ET More on Genmab, Seagen, etc. Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Genmab Is Down To Attractive Levels Genmab A/S ( GMAB ) Q2 2023 Earnings Call Transcript Genmab: Epkinly's Appr...

Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a future medical meeting Genmab and Seagen to engage i...

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK ® (tisotumab vedotin-tftv), compared w...

2023-08-31 05:42:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite polls showing most Americans are unhappy with the state of the economy, President Biden has defended his policies with claims he is improving the finances and living standards ...

2023-08-30 11:17:45 ET Summary Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the treatment of DLBCL is a significant milestone for Genmab and Epkinly has the potential to become on...

2023-08-03 17:58:02 ET Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief Development Officer Anthony M...